CA2089959A1 - Use of xanthine derivatives for the treatment of muscle damage after interruption of the blood circulation - Google Patents

Use of xanthine derivatives for the treatment of muscle damage after interruption of the blood circulation

Info

Publication number
CA2089959A1
CA2089959A1 CA002089959A CA2089959A CA2089959A1 CA 2089959 A1 CA2089959 A1 CA 2089959A1 CA 002089959 A CA002089959 A CA 002089959A CA 2089959 A CA2089959 A CA 2089959A CA 2089959 A1 CA2089959 A1 CA 2089959A1
Authority
CA
Canada
Prior art keywords
formula
carbon atoms
interruption
methyl
blood circulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002089959A
Other languages
English (en)
French (fr)
Inventor
Ismahan Okyayuz-Baklouti
Maurice Mars
Michael Alfred Gregory
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of CA2089959A1 publication Critical patent/CA2089959A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002089959A 1992-02-22 1993-02-19 Use of xanthine derivatives for the treatment of muscle damage after interruption of the blood circulation Abandoned CA2089959A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4205424.9 1992-02-22
DE4205424 1992-02-22

Publications (1)

Publication Number Publication Date
CA2089959A1 true CA2089959A1 (en) 1993-08-23

Family

ID=6452327

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002089959A Abandoned CA2089959A1 (en) 1992-02-22 1993-02-19 Use of xanthine derivatives for the treatment of muscle damage after interruption of the blood circulation

Country Status (13)

Country Link
EP (1) EP0557876B1 (enrdf_load_html_response)
JP (1) JP3193800B2 (enrdf_load_html_response)
KR (1) KR930017580A (enrdf_load_html_response)
AT (1) ATE146078T1 (enrdf_load_html_response)
AU (1) AU658979B2 (enrdf_load_html_response)
CA (1) CA2089959A1 (enrdf_load_html_response)
DE (1) DE59304710D1 (enrdf_load_html_response)
DK (1) DK0557876T3 (enrdf_load_html_response)
ES (1) ES2096115T3 (enrdf_load_html_response)
GR (1) GR3022183T3 (enrdf_load_html_response)
HU (1) HUT64472A (enrdf_load_html_response)
TW (1) TW288977B (enrdf_load_html_response)
ZA (1) ZA931184B (enrdf_load_html_response)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3792266B2 (ja) * 1994-06-16 2006-07-05 森精機興産株式会社 工作機械の熱変位補正方法及びその装置
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
WO2007041506A1 (en) * 2005-10-03 2007-04-12 Melior Discovery, Inc. Purine formulations and methods for managing disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH608236A5 (enrdf_load_html_response) * 1974-01-22 1978-12-29 Wuelfing J A Fa
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
ATE138266T1 (de) * 1990-11-07 1996-06-15 Hoechst Roussel Pharma Verwendung von xanthinen zur herstellung von arzneimitteln zur hemmung der vermehrung menschlicher retroviren

Also Published As

Publication number Publication date
ES2096115T3 (es) 1997-03-01
JPH069634A (ja) 1994-01-18
AU3376193A (en) 1993-08-26
DE59304710D1 (de) 1997-01-23
KR930017580A (ko) 1993-09-20
ATE146078T1 (de) 1996-12-15
HUT64472A (en) 1994-01-28
EP0557876A1 (de) 1993-09-01
JP3193800B2 (ja) 2001-07-30
DK0557876T3 (da) 1997-05-26
TW288977B (enrdf_load_html_response) 1996-10-21
ZA931184B (en) 1993-09-16
HU9300476D0 (en) 1993-05-28
EP0557876B1 (de) 1996-12-11
GR3022183T3 (en) 1997-03-31
AU658979B2 (en) 1995-05-04

Similar Documents

Publication Publication Date Title
RU95113148A (ru) Производное 2-(2-амино-1,6-дигидро-6-оксопурин-9-ил)-метокси-1,3-пропандиола
EP1961420B1 (en) Agent for prevention and treatment of acute renal failure
CA2089959A1 (en) Use of xanthine derivatives for the treatment of muscle damage after interruption of the blood circulation
AU2005205166B2 (en) Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof
RU2303041C2 (ru) Твердые соли бензазепиновых соединений и их применение при получении фармацевтических соединений
KR0133075B1 (ko) 소화성 궤양 질환 치료용 치료학적 제제
EP0305277A2 (fr) Application de l'amino-2 trifluoro-méthoxy-6 benzothiazole pour obtenir un médicament destiné au traitement des troubles du sommeil et de la dépression
DK170645B1 (da) Krystallinsk vandfrit amoxycillin, fremgangsmåde til fremstilling heraf, samt præparater indeholdende dette
RU2131246C1 (ru) Агент, ускоряющий разрастание эндотелиальных клеток
KR20090033405A (ko) 알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에 아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를 제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는 방법
JPH05246850A (ja) 脳循環の自己調節を安定化するためのキサンチン誘導体の使用
EP0266559A2 (en) Therapeutic agent for the treatment of peptic ulcer disease
AU651205B2 (en) The use of 1-(5-oxohexyl)-3-methyl-7-n-propylxanthine in vascular surgery
JP2977242B2 (ja) 抗消化性潰瘍剤
WO2002078710A1 (fr) Medicaments contre l'hyperactivite vesicale
WO2020173495A1 (zh) 醛糖还原酶抑制剂的盐及其制备方法和应用
BE896621A (fr) Nouvelle utilisation therapeutique d'analogues de prostaglandines
WO1992003134A1 (en) New pharmaceutical formulations of 5-(2-chloro-1-hydroxyethyl)-4-methylthiazole
FR2481704A1 (fr) Extrait de plantes du genre epimadium sp procede pour la preparation de cet extrait, agent immunostimulant comprenant cet extrait comme composant actif et immunotherapie obtenue en utilisant cet extrait
WO2000056336A2 (en) Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin
EP0653206A1 (en) Anti-hiv agent
JPH05112463A (ja) 白内障治療剤
US4786634A (en) Method for treating arteriosclerosis
JPH0621071B2 (ja) 血小板凝集抑制剤
JPH09506883A (ja) 薬 剤

Legal Events

Date Code Title Description
FZDE Discontinued